Scholars Central

Conference abstract

Nano-RNAi? functionalized polyvalent gold nanoparticles as novel anti-glioma therapeutics

Authors: Alexander H. Stegh

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Glioblastoma (GBM) is a lethal brain tumor characterized by resistance to extant chemo-, radiation and targeted therapies. Bcl2L12 (for Bcl2-Like 12) is a cytoplasmic and nuclear glioma oncoprotein that is over-expressed in >90% of primary GBM and confers resistance toward therapy-induced apoptosis. On the molecular levels, Bcl2L12 binds and inhibits caspase-7 and blocks caspase-3 maturation through up-regulation of the small heat shock protein and caspase-3-specific inhibitor α B-crystalline. In addition, nuclear Bcl2L12 physically interacts with the p53 tumor suppressor and robustly represses p53 transactivational activities. To therapeutically suppress Bcl2L12?s diverse and potent gliomagenic activities, we employed a gene silencing approach using small interfering RNA (siRNA)-conjugated polyvalent gold nanoparticles (RNA-Au-NPs) to knockdown and inactivate Bcl2L12 signaling in glial cells. Our studies document that RNA-Au-NPs exhibit superior biological stability, highly significant knockdown efficacies, robust cellular uptake, and biocompatible intratumoral delivery upon systemic i.v., and local administration, reduced off-target effects, and diminished activation of innate immune responses compared to conventional, lipoplex-delivered RNAi. In particular, we could show that RNA-Au-NPs are single entity agents, which are 500 times more effective in knocking down Bcl2L12 than conventional RNAi-based methods and do not require auxiliary transfection agents. MRI studies using Gd (III)-conjugated RNA-Au-NPs confirmed that these nanomaterials penetrate intracranial brain tumors highly effectively without the need for convection-based enhanced delivery. Nano-RNAi- mediated knockdown of Bcl2L12 resulted in sensitization of cells toward apoptosis, and prolonged survival of glioma-bearing mice. Thus, silencing Bcl2L12 signaling by nano- RNAi represents a novel therapeutic approach to restrain GBM pathogenesis.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Nanomedicine & Nanotechnology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Nanomedicine & Nanotechnology
  • SubjectNanotechnology
  • BylineArticles whose byline prints “Alexander H. Stegh”